TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

  title={TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases},
  author={Marc Feldmann and Ravinder Nath Maini},
  journal={Nature Medicine},
Nat. Med. 9, 1245–1250 (2003) A callout for Figure 3 should have been inserted on p. 1248. The last sentence of the first paragraph of column 3 should read, “...the relative rarity of sustained remission of disease (Fig. 3).” We regret the error. 
Anti-TNF Therapy: 20 Years from Our First Therapeutic Adventure
Anti-tumor necrosis factor (TNF) therapy was the first successful anti-cytokine therapy, and its discovery was based on detailed examination of human disease tissue in rheumatoid arthritis and on
Anti-TNF therapy from the bench to the clinic: a paradigm of translational research.
In the 1980s emerging recombinant DNA and monoclonal antibody technology stimulated research into the molecular concepts of pathogenesis of disease. A number of cytokines were being identified and
Immune Mechanisms and Novel Targets in Rheumatoid Arthritis.
  • S. Venuturupalli
  • Medicine, Biology
    Immunology and allergy clinics of North America
  • 2017
Infliximab treatment of rheumatoid arthritis.
  • S. R. Maini
  • Medicine
    Rheumatic diseases clinics of North America
  • 2004
Rheumatoid arthritis: Evolving recognition of a common disease.
  • D. Daikh
  • Biology, Medicine
    Best practice & research. Clinical rheumatology
  • 2022
Anti-TNF treatment in rheumatoid arthritis.
The intense efforts currently being made to identify biomarkers of response to anti-TNF therapy and recent progress in defining genetic predictors of response using genome- wide association studies (GWAS) are covered.
Workshop summary: functions of the TNF family in infectious disease.
Some of the key findings and unifying themes that are discussed in more depth in the chapters that follow are summarized.
Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis.


Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group.
In patients with persistently active rheumatoid arthritis despite methotrexate therapy, repeated doses of infliximab in combination with methotRexate provided clinical benefit and halted the progression of joint damage.
Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.
Preliminary results support the hypothesis that TNF alpha is an important regulator in RA, and suggest that it may be a useful new therapeutic target in this disease.
Inhibition of the production and effects of interleukins‐1 and tumor necrosis factor α in rheumatoid arthritis
The evidence to date shows that 5 of 6 criteria for identifying mediators of tissue damage in human autoimmune diseases are satisfied and the last criterion, prevention of clinical progression in patients with RA, is currently being evaluated.
Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.
In this three-month trial TNFR:Fc was safe, well tolerated, and associated with improvement in the inflammatory symptoms of rheumatoid arthritis.
Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?
Clinical investigations in which the activity of TNF alpha in RA patients was blocked with intravenously administered infliximab, a chimeric anti-TNF alpha monoclonal antibody (mAB), has provided evidence that TNF regulates IL-6, IL-8, MCP-1, and VEGF production, recruitment of immune and inflammatory cells into joints, angiogenesis, and reduction of blood levels of matrix metalloproteinases-1 and -3.
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial.
The addition of adalimumab at a dosage of 20 mg, 40 mg, or 80 mg administered subcutaneously every other week to long-term MTX therapy in patients with active RA provided significant, rapid, and sustained improvement in disease activity over 24 weeks compared with MTX plus placebo.
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).